Elysium plans to launch its mainnet on November 9, introducing the first layer-2 network within the Hyperliquid ecosystem. This new network will operate on HyperEVM, Hyperliquid's smart contract environment, and use Hyperliquid's native token HYPE for transaction fees. Elysium will work alongside HyperCore, which manages trading activities, enhancing the infrastructure for developers to build applications connected to Hyperliquid's trading platform. The launch marks Elysium's transition from testing to a live network for applications and transactions.
Elysium's upcoming mainnet launch on November 9 provides context for cryptocurrency market activity. For readers following crypto, here is Pluang's market snapshot as of Oct 19, 2026 19:21 WIB: out of 50 major cryptocurrencies, 23 rose and 25 fell. CAKE traded at Rp38.748 with a 1-day change of -2.02%, ENJ was at Rp486 with a -1.94% change, and AXS stood at Rp18.008 with a -1.89% change.
Disc Medicine's stock surged 38% following positive Phase 3 trial results for its drug bitopertin, which showed efficacy and safety in treating erythropoietic protoporphyria. BMO Capital raised its price target from $100 to $120 and maintained an Out...
Qualcomm executive Ann C. Chaplin sold 1,827 shares of the company's stock for $319,268.25 under a Rule 10b5-1 trading plan, reducing her holdings by 6.62%. Qualcomm's stock price recently traded below its 50-day and 200-day moving averages, signalin...
BOK Financial is set to announce its Q3 2026 earnings after market close on October 19, with analysts forecasting earnings per share between $2.52 and $2.54 and revenue near $571 million. The company has a strong history of surpassing earnings estima...
AIBotics has completed the acquisition of NovaCore Labs' assets from PlayJamaica Limited, gaining technology, software, drones, mapping equipment, and customer contracts. This move expands AIBotics' platform in Jamaica and the Caribbean, enhancing AI...
EyePoint's stock dropped sharply after its DURAVYU treatment did not meet the primary endpoint in a Phase 3 trial for wet age-related macular degeneration (wet AMD). Although DURAVYU showed some vision improvement and reduced the need for additional ...
